Sanofi Pasteur, Merck Part Ways On European Vaccines Venture
This article was originally published in Scrip
Sanofi Pasteur MSD - the joint venture in Europe between Sanofi SA's vaccine arm and Merck & Co – is ending after 22 years as the duo believes they can better manage their product portfolios independently.
You may also be interested in...
At year's end the French pharma also announced a restructuring of its broad diabetes collaboration with South Korea’s Hanmi. In a deal involving two other French companies, OSE out-licensed global development and commercial rights to an IL-7 antagonist to Servier.
Sanofi clearly would benefit from its proposed $9.3bn purchase of Medivation Inc. based on the French company's first quarter earnings, which show a pharmaceuticals business that's suffering from competition, US drug pricing pressures and foreign currency exchange issues.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.